Operates as an anti-infective drug development company
Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections.
Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics, currently being evaluated in ongoing Phase 2b SPIRITUS trial; BTA074, a Phase 2 topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor in Phase 1 development for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment in Phase 2 development for influenza A and B infections.
The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
|Vote ||Quantity||Float||Company-owned shares||Total Float
|Broadfin Capital LLC ||3,486,711||
|East Hill Management Co. LLC ||3,456,520||
|Krensavage Asset Management LLC ||2,713,517||
|Senzar Asset Management LLC ||1,779,976||
|The Vanguard Group, Inc. ||1,044,243||
|Renaissance Technologies LLC ||665,158||
|BlackRock Fund Advisors ||588,061||
|Fidelity Management & Research Co. ||390,000||
|Stonepine Capital Management LLC ||347,440||
|Landon Thomas Clay ||327,672||
|Biota Pharmaceuticals Inc : Connections|
|Aviragen Therapeutics, Inc.|
2500 Northwinds Parkway
Alpharetta, GA 30009
Phone : +1.678.221.3343
Web : www.aviragen.com
© 2016 People , Fundamentals and Ownership